Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    alpharadin | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
Conditions: Clear-cell Metastatic Renal Cell Carcinoma;   Bone Metastases
Intervention: Drug: XOFIGO
2 Recruiting BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Condition: Non Small Cell Lung Cancer With Bone Metastatses
Intervention: Biological: Xofigo
3 Recruiting Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY 88-8223)
4 Recruiting Phase II Trial of Ra-223 Dichloride and Hormonal Treatment
Condition: Breast Cancer
Interventions: Drug: Ra-223 dichloride;   Drug: Denosumab;   Drug: Hormone Therapy
5 Recruiting Radium 223 Following Intermittent ADT
Condition: Prostate Cancer
Intervention: Radiation: Radium 223 Dichloride (Xofigo®)
6 Recruiting Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Condition: Castration-Resistant Prostatic Cancer
Intervention: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)
7 Recruiting Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Radium-223-dichloride (Xofigo, BAY88-8223)
8 Not yet recruiting Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: Xofigo (Radium-223 dichloride, BAY88-8223
9 Recruiting Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Radiation: Radium 223
10 Recruiting Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
Condition: Prostate Carcinoma
Interventions: Drug: Radium-223 dichloride;   Other: Conventional or high dose radiotherapy
11 Not yet recruiting Treatment Patterns in Metastatic Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: Xofigo (Radium 223 dichloride,BAY88-8223)
12 Recruiting NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Prostate Carcinoma
Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Sodium Fluoride;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
13 Recruiting Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Condition: Prostate Cancer
Interventions: Drug: Radium-223;   Biological: Sipuleucel-T
14 Not yet recruiting Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
15 Recruiting Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Other: Background hormonal therapy
16 Recruiting Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
17 Recruiting Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
18 Recruiting Radium-223 Dichloride Long-term Follow-up Program
Condition: Neoplasm Metastasis / Bone and Bones
Intervention: Other: Data Collection

Indicates status has not been verified in more than two years